Pfizer has agreed to acquire FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company. Pfizer will make an upfront payment as well as milestone payments, but financial terms were not disclosed. The closing is expected later this year. FoldRx’s portfolio includes clinical and preclinical programs for investigational compounds to treat diseases caused by protein misfolding, which is recognized as an underlying cause in many chronic degenerative diseas...